Introduction
============

Inhaled long-acting β~2~-agonists (LABAs), alone or in combination with inhaled corticosteroids (ICS), improve lung function and clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).[@b1-copd-11-381]--[@b3-copd-11-381] Some outcomes, such as improvements in exercise capacity and breathlessness, occur after a single dose of a bronchodilator.[@b4-copd-11-381],[@b5-copd-11-381] However, for other important events, such as exacerbations, time must elapse before the effect of treatment is clear. The current recommendations for treatments that prevent exacerbations, an important future risk for patients with COPD,[@b6-copd-11-381] are based on the average benefit of therapy seen in large patient populations, normally in trials of 12 months' duration. Identification of an easily measurable disease marker that identifies individuals likely to benefit from continued treatment would aid clinical decision making and prognostication.

Two potential markers of early treatment effect are the change in lung function and in health status during treatment, evaluated by change in forced expiratory volume in 1 second (FEV~1~) and St George's Respiratory Questionnaire (SGRQ) total score, respectively. Both markers improve within days or weeks of bronchodilator treatment,[@b7-copd-11-381]--[@b9-copd-11-381] and each has a defined clinically important difference (CID) that could serve as a threshold to identify change. A 100 mL increase in FEV~1~ during the recovery period from an exacerbation identified patients less likely to have a subsequent relapse, lending support to the utility of this threshold for CID.[@b10-copd-11-381] However, before accepting these variables as being useful, it is crucial to determine: 1) the prevalence of early CID in these outcomes related to treatment; 2) the consistency of early responses over time; and 3) the impact of early response on future exacerbation risk.

To address these questions, we performed a post hoc analysis of data from published trials in which the LABA for-moterol, given alone via a dry powder inhaler, was compared with a fixed-dose combination of formoterol and the ICS budesonide, given via a pressurized metered-dose inhaler, over 6--12 months in patients with moderate-to-very-severe COPD at risk of exacerbations.[@b3-copd-11-381],[@b11-copd-11-381],[@b12-copd-11-381]

Methods
=======

Study design and patient population
-----------------------------------

This post hoc analysis is based on data from three multicenter, randomized, double-blind, double-dummy, parallel-group clinical trials of 6 ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT00206154[@b3-copd-11-381]) and 12 (NCT00206167[@b11-copd-11-381] and NCT00419744[@b12-copd-11-381]) months' duration in patients with moderate-to-very-severe COPD.

The studies recruited patients ≥40 years of age with COPD and symptoms for \>2 years, a smoking history of ≥10 pack-years, prebronchodilator FEV~1~ ≤50% predicted, FEV~1~/forced vital capacity ratio of \<0.7, modified Medical Research Council dyspnea score ≥2, and a history of ≥1 COPD exacerbation requiring systemic corticosteroids and/or antibiotics within 1--12 months of inclusion. Patients were randomized to receive two inhalations twice daily of budesonide/formoterol 160/4.5 µg (via pressurized metered-dose inhaler) or formoterol 4.5 µg (via dry powder inhaler) for 6[@b3-copd-11-381] or 12[@b11-copd-11-381],[@b12-copd-11-381] months. Two studies[@b3-copd-11-381],[@b11-copd-11-381] included a placebo control group. All participants provided written informed consent and the studies received appropriate ethical approval.

Study assessments
-----------------

All studies assessed prebronchodilator FEV~1~ and SGRQ total score at baseline and 2 months postrandomization and, in two of the studies,[@b11-copd-11-381],[@b12-copd-11-381] also at 12 months. Spirometry was performed according to the American Thoracic Society guidelines.[@b13-copd-11-381] COPD exacerbations, defined as worsening symptoms requiring oral corticosteroids and/or hospitalization, were recorded throughout the study periods.

In the present analysis, changes in FEV~1~ (≥100 mL improvement in prebronchodilator FEV~1~[@b8-copd-11-381],[@b14-copd-11-381],[@b15-copd-11-381]) and SGRQ total score (≥4-point decrease \[ie, an improvement\][@b16-copd-11-381]) from 0 to 2 months were used as thresholds to investigate the frequency of response over 0--2 months of treatment (a commonly used clinical follow-up interval). From these 2-month responses, we investigated: 1) the stability of early 2-month FEV~1~ and SGRQ responses in the two 12-month studies[@b11-copd-11-381],[@b12-copd-11-381] and 2) the rate of exacerbations during months 2--12 in the responder subgroups of all three studies.[@b3-copd-11-381],[@b11-copd-11-381],[@b12-copd-11-381] Data from the placebo-controlled studies[@b3-copd-11-381],[@b11-copd-11-381] were analyzed to provide information about spontaneous improvement in the early response measurement. The 6-month study was included in order to evaluate short-term response, including placebo as a control; this approach was necessary in order to achieve the optimum number of patients.

Data analyses and statistical methods
-------------------------------------

Both FEV~1~ and SGRQ data were described as continuous variables and binary outcomes defined by their respective thresholds.

Changes in FEV~1~ and SGRQ total score from 0 to 2 months were compared between treatments using analysis of variance, with treatment and study as factors and the baseline value as a covariate. The proportion of patients achieving an FEV~1~ or SGRQ response during 0--2 months was compared between all treatments using logistic-regression analysis, with treatment and study as factors. The responder analysis from 0 to 2 months postrandomization excluded patients with missing baseline FEV~1~ or SGRQ total score data.

The 0--12-month analysis was restricted to the formoterol and budesonide/formoterol groups because of high dropout rates in the placebo groups during the follow-up period of the studies, a finding noted previously.[@b17-copd-11-381] Changes in FEV~1~ and SGRQ total score from 0 to 12 months were analyzed using a linear model, with treatment and study as factors and baseline values and change from 0 to 2 months as covariates. The odds ratio (OR), with 95% confidence intervals (CIs), of being a 12-month responder was analyzed using logistic-regression analysis with study, treatment, and 2-month response as factors. The interaction between treatment allocation and 2-month FEV~1~ and SGRQ response rates was also investigated.

In subjects achieving thresholds of ≥100 mL improvement in FEV~1~ and a decrease of ≥4 points in SGRQ total score at 2 months, exacerbation rates (events per patient per year) by response and treatment were estimated using a Poisson model, with treatment, study, response, and treatment response interaction as factors. Rate ratios between treatments and response groups, with 95% CIs and *P*-values, were calculated. In addition, exacerbation rates after the 2-month visit were analyzed using a Poisson model with treatment and study as factors; covariates were baseline values and change in FEV~1~ and SGRQ total scores over 0--2 months, adjusted for the remaining observation time and over-dispersion.

Results
=======

Patient demographics and clinical characteristics
-------------------------------------------------

A total of 2,331 and 1,799 patients were included in the 0--2[@b3-copd-11-381],[@b11-copd-11-381] and 0--12-month[@b11-copd-11-381],[@b12-copd-11-381] responder analyses, respectively, and 2,360 patients were included in the 2--12-month exacerbation rate analysis.[@b3-copd-11-381],[@b11-copd-11-381],[@b12-copd-11-381] Missing data are described in the supplementary materials. There were no significant differences in baseline clinical or demographic characteristics among the three analyses ([Table 1](#t1-copd-11-381){ref-type="table"}) and between the three different treatment groups included in the 0--2-month responder analysis ([Table 2](#t2-copd-11-381){ref-type="table"}).

Two-month response in FEV~1~ and SGRQ as a predictor of longer-term response to ICS/LABA or LABA
------------------------------------------------------------------------------------------------

At 2 months, an FEV~1~ response (≥100 mL improvement) was seen in 35.1% of patients (Figure S1A) and an SGRQ response (≥4-point improvement in total score) was seen in 44.3% of patients (Figure S2A). FEV~1~ responders had better baseline lung function and SGRQ responders had higher initial SGRQ total scores than the respective nonresponders (Tables S1 and S2). Responders took fewer maintenance medications (long-acting bronchodilators or ICS) at study entry than nonresponders (Tables S1 and S2).

The odds of being an FEV~1~ and SGRQ responder were significantly greater with budesonide/formoterol versus formoterol alone (OR, 1.56 \[*P*\<0.001\] and OR, 1.36 \[*P*\<0.006\], respectively) and for budesonide/formoterol versus placebo (OR, 2.21 \[*P*\<0.001\] and OR, 1.42 \[*P*=0.002\], respectively) ([Table 3](#t3-copd-11-381){ref-type="table"}). The budesonide/formoterol group had higher response rates than either formoterol- or placebo-treated patients over a range of cut-points for FEV~1~ and SGRQ score ([Figure 1A and B](#f1-copd-11-381){ref-type="fig"}, respectively).

At 12 months, the prespecified FEV~1~ and SGRQ responses were seen in 36.0% (Figure S1B) and 49.0% (Figure S2B) of patients, respectively. Responses at 2 months were highly predictive of 12-month response: an FEV~1~ response at 12 months was 5.6 times more likely among 2-month responders than nonresponders (OR, 5.57; 95% CI, 4.14--7.50; *P*\<0.001) and a 12-month SGRQ response was 3.9 times more likely if the patient responded at 2 months (OR, 3.87; 95% CI, 2.83--5.31; *P*\<0.001).

Two-month response in FEV~1~ and SGRQ as a predictor of exacerbations
---------------------------------------------------------------------

Exacerbations during months 2--12 were significantly less frequent in FEV~1~ 2-month responders than in nonresponders (*P*\<0.001; [Table 4](#t4-copd-11-381){ref-type="table"}). This effect was observed in both treatment groups. In 2-month FEV~1~ responders, reductions in 12-month exacerbation rates were similar for budesonide/formoterol and formoterol alone ([Table 4](#t4-copd-11-381){ref-type="table"}). In 2-month FEV~1~ nonresponders, the 12-month exacerbation rate was significantly lower for budesonide/formoterol-treated patients compared with formoterol alone (*P*=0.015; [Table 4](#t4-copd-11-381){ref-type="table"}; [Figure 2A](#f2-copd-11-381){ref-type="fig"}). Exacerbation frequency during months 2--12 was unrelated to SGRQ response at 2 months (32.2% vs 34.2%; [Table 4](#t4-copd-11-381){ref-type="table"}; [Figure 2B](#f2-copd-11-381){ref-type="fig"}). However, exacerbations were less frequent with the budesonide/formoterol combination, irrespective of 2-month SGRQ response ([Table 4](#t4-copd-11-381){ref-type="table"}; [Figure 2B](#f2-copd-11-381){ref-type="fig"}).

A Poisson analysis with treatment, baseline, and 2-month response as factors showed that improvements in 2-month FEV~1~ of ≥100 mL and SGRQ total score of ≥4 points were associated with an 8% and 5% decrease, respectively, in exacerbation frequency during months 2--12 ([Table 5](#t5-copd-11-381){ref-type="table"}). Greater FEV~1~ (100 mL) and lower SGRQ score (−4 points) at baseline were also predictive of a decrease in exacerbation frequency ([Table 5](#t5-copd-11-381){ref-type="table"}).

Discussion
==========

In this post hoc analysis of data from published trials, we have shown that: 1) improvements in FEV~1~ and SGRQ total score after 12 months are more likely to be observed in patients showing an early 2-month treatment response compared with 2-month nonresponders; 2) a 2-month treatment response in FEV~1~, but not SGRQ, was associated with greater reductions in exacerbation risk; and 3) 2-month FEV~1~ and SGRQ non-responders had fewer exacerbations if they received an ICS/LABA rather than a LABA alone. These data help set the "early response" to treatment in a wider context.

Our analysis sought to establish whether early responses to treatment have predictive ability by measuring changes in FEV~1~ and SGRQ total score after 2 months of treatment. It was expected that changes in these variables would be clinically noticeable after 2 months, a follow-up interval commonly used in clinical practice when assessing the impact of treatment in patients with COPD. Although somewhat arbitrary, an improvement of 100 mL in FEV~1~ appears to be a reasonable threshold as it exceeds the day-to-day reproducibility of this measurement in patients with COPD,[@b18-copd-11-381] identifies patients with a lower risk of relapse during recovery from an acute event,[@b8-copd-11-381] and has previously been proposed as the minimal CID between measurements.[@b15-copd-11-381] A change in SGRQ total score of ≥4 units has been validated as a minimal CID in health status measured in mild-to-severe COPD with this questionnaire.[@b19-copd-11-381] Changes of this magnitude have been observed in short- and longer-term trials of bronchodilators in COPD.[@b1-copd-11-381],[@b7-copd-11-381],[@b10-copd-11-381] Data from the placebo arms of our analysis show that spontaneous increases in FEV~1~ sufficient to exceed the 100 mL threshold were less frequent than 4-point improvements in the SGRQ total score, reflecting the multiple factors that influence health status measurement.

Patients meeting our FEV~1~ response criterion had better baseline lung function and took less maintenance medication at study entry than nonresponders. These data support other studies showing that acute postbronchodilator improvements in FEV~1~ are greater in patients with less severe disease.[@b20-copd-11-381],[@b21-copd-11-381] The chances of a response in SGRQ total score from 0 to 2 months were greater than those for FEV~1~ response. This was unrelated to baseline lung function but was more likely if the initial SGRQ total score was high, raising the possibility of regression to the mean in some cases.

Predicting longer-term response to treatment
--------------------------------------------

Over the trial period, 80% of FEV~1~ nonresponders at 2 months remained in this group at 12 months, while FEV~1~ responders showed more variation, with only 58% of these showing a 100 mL improvement in FEV~1~ at 2 months still remaining responders at 12 months. In contrast, SGRQ responders were more likely to sustain their initial improvement and in addition, more patients became responders over time. Despite these encouraging findings in the whole group, it would be difficult to advise an individual patient about his or her future lung function or health status based on the change in health status at 2 months.

Predicting future exacerbation risk
-----------------------------------

The investigation of an early response to treatment as a predictor of future risk differs from previously published studies, which have investigated the predictive utility of baseline values. For example, the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (NCT00292552) study[@b22-copd-11-381] showed that a wide range of baseline FEV~1~ and SGRQ values were predictive of exacerbation outcomes. Furthermore, a post hoc analysis by Make et al[@b23-copd-11-381] observed that all baseline lung function variables studied were strong predictors of severe exacerbations. Conversely, other studies have suggested that there is no relationship between airflow obstruction characteristics and exacerbation rates.[@b24-copd-11-381],[@b25-copd-11-381]

Based on these contrasting observations, it is clear that additional predictors of exacerbation frequency are needed, and our data show that early response to treatment offers an alternative approach, which has predictive value in some (those patients with an early response to FEV~1~, ie, 35.1% of patients in our study), but not all patients. A 2-month FEV~1~ response of ≥100 mL for both formoterol and budesonide/formoterol identified patients less likely to exacerbate during follow-up. In general, the greater the improvement in FEV~1~, the lower the chance of a future exacerbation, although we cannot exclude the possibility that other factors may contribute to both an FEV~1~ response and a reduction in exacerbations. However, FEV~1~ response at 2 months was not the only predictive factor, as a between-treatment difference in exacerbation risk was still present in nonresponders. This may reflect the smaller FEV~1~ responses seen in patients with worse initial lung function,[@b26-copd-11-381] as changes in operating lung volume rather than FEV~1~ are important drivers of exacerbation in such patients.[@b27-copd-11-381] Our data extend the observations from indacaterol trials where change in trough FEV~1~ at 12 weeks was related to change in exacerbation risk and dyspnea score, although a specific, arbitrary threshold value was not utilized.[@b10-copd-11-381]

Despite the baseline level of health status predicting an overall risk of exacerbation in our study, SGRQ response at 2 months was not predictive of exacerbation risk over 2--12 months. Health status is adversely affected by disease exacerbations,[@b28-copd-11-381] and the change in SGRQ total score at 2 months may reflect variables other than an effect of exacerbation prevention. Although reverse causality cannot be excluded, it seems more likely that an SGRQ total score responds to previous exacerbation events rather than predicting the risk of future events. Thus, while a significant association is shown for FEV~1~, no such link is evident for SGRQ over the score range in the current analysis.

Areas for further study
-----------------------

There may be other markers of an early treatment effect than those analyzed here. One example could be lung hyperinflation, which is not reflected in routine spirometry and may be used to measure therapeutic response; however, our analysis provides evidence based on responses that are more easily measured in primary care. Blood eosinophil count may also be a parameter for response to ICS in patients with COPD,[@b29-copd-11-381] but such data were not available for analysis.

Whether a change that exceeds our threshold values occurs at earlier time points and is a comparable or better predictor of clinical outcome also needs to be determined. Defining responses by early FEV~1~ response has some utility when the therapy has the potential to alter that variable, although this is not true for all interventions.[@b26-copd-11-381]

Other considerations
--------------------

This study has some limitations. Our analysis restricted the placebo comparisons to the early 2-month response analysis as missing data due to early dropouts significantly reduced data quality in the placebo arms of the relevant studies, as noted previously.[@b1-copd-11-381] The issue of missing data is a frequent problem in trials of COPD therapy. The absence of data in 15% of patients over a 12-month period is not unusual for analyses of this type. Loss of data due to discontinuation in clinical trials of this type is more frequent on the less effective treatment,[@b30-copd-11-381] which in the present analysis is formoterol.

Our data were derived from a clinical trial population, yet we believe that they have wider clinical relevance as the necessity of adding an ICS to a long-acting bronchodilator in patients with COPD, and assessing its benefit, is an important therapeutic consideration in both primary and secondary care. These data also show that a greater proportion of patients with COPD receiving budesonide/formoterol demonstrate a positive treatment response compared with those receiving formoterol alone.

Conclusion
==========

FEV~1~ and SGRQ are commonly used in specialist clinics to assess patient progress. Our results, which were obtained in patients with moderate-to-very-severe COPD who had an exacerbation in the previous year, suggest that an early response at 2 months in either domain is associated with better long-term outcomes in that domain and, in the case of improvement in FEV~1~, a lower chance of future exacerbations. However, such changes occur in a minority of cases and therapeutic benefit can also occur in patients who do not have an "early" response to treatment. Further investigations and prospective studies are needed to identify more sensitive and specific markers of a favorable treatment response. The need to assess patients soon after treatment is changed is worth considering.
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![Cumulative distribution of (**A**) FEV~1~ response and (**B**) SGRQ response at 2 months in patients who received budesonide/formoterol, formoterol alone, or placebo, by treatment, according to multiple cut-points.\
**Note:** Vertical lines represent the predefined response cut-offs (+100 mL for FEV~1~ and −4 points for SGRQ total score).\
**Abbreviations:** BUD, budesonide; FEV~1~, forced expiratory volume in 1 second; FORM, formoterol; SGRQ, St George's Respiratory Questionnaire.](copd-11-381Fig1){#f1-copd-11-381}

![Exacerbation rates during months 2--12 in patients who received budesonide/formoterol or formoterol alone and who achieved (**A**) FEV~1~ response and (**B**) SGRQ improvements above various thresholds at 2 months.\
**Note:** Vertical lines represent the predefined response cut-offs (+100 mL for FEV~1~ and −4 points for SGRQ total score).\
**Abbreviations:** BUD, budesonide; FEV~1~, forced expiratory volume in 1 second; FORM, formoterol; SGRQ, St George's Respiratory Questionnaire.](copd-11-381Fig2){#f2-copd-11-381}

###### 

Demographic and clinical characteristics of patients who received budesonide/formoterol, formoterol alone, or placebo in the 0--2-month responder analysis, and budesonide/formoterol or formoterol alone in the 12-month response and 2--12-month exacerbation rate analyses[a](#tfn2-copd-11-381){ref-type="table-fn"}

  Characteristics                                                                            0--2-month response analysis (n=2,331)   12-month response analysis (n=1,799)   Exacerbation rate analysis (n=2,360)
  ------------------------------------------------------------------------------------------ ---------------------------------------- -------------------------------------- --------------------------------------
  Age, years                                                                                 63.1 (9.2)                               63.1 (9.2)                             63.1 (9.2)
  Male, n (%)                                                                                1,526 (65.5)                             1,122 (62.4)                           1,496 (63.4)
  BMI, kg/m^2^                                                                               26.8 (5.7)                               26.7 (5.9)                             26.6 (5.8)
  Time since first symptoms, months                                                          127.2 (84.8)                             126.5 (85.3)                           125.6 (85.2)
  FEV~1~ parameters                                                                                                                                                          
   Prebronchodilator, % predicted                                                            34.2 (9.7)                               34.7 (10.4)                            34.4 (10.3)
   Prebronchodilator,[b](#tfn3-copd-11-381){ref-type="table-fn"} L                           1.0 (0.4)                                1.0 (0.4)                              1.0 (0.4)
   Reversibility, % predicted                                                                5.5 (5.9)                                5.4 (5.6)                              5.4 (5.6)
   Postbronchodilator, % predicted                                                           39.7 (11.9)                              40.0 (12.4)                            39.9 (12.4)
  Prebronchodilator FEV~1~/FVC, %                                                            47.6 (10.4)                              47.0 (10.8)                            46.8 (10.7)
  Smoking history                                                                                                                                                            
   Median, pack-years                                                                        40.0                                     43.0                                   42.0
   Former smokers, n (%)                                                                     1,343 (57.6)                             1,091 (60.6)                           1,410 (59.8)
   Current smokers, n (%)                                                                    988 (42.4)                               708 (39.4)                             950 (40.3)
  SGRQ total score,[b](#tfn3-copd-11-381){ref-type="table-fn"} points (range)                54.9 (6.7--100.0)                        56.1 (6.2--100.0)                      55.8 (6.2--100.0)
  Reliever use, no of inhalations (range)                                                    3.7 (0.0--32.5)                          4.8 (0.0--33.8)                        4.5 (0.0--33.8)
  COPD severity (GOLD grades),[c](#tfn4-copd-11-381){ref-type="table-fn"} n (%)                                                                                              
   II (moderate)                                                                             436 (18.7)                               386 (21.6)                             497 (21.2)
   III (severe)                                                                              1,364 (58.5)                             981 (55.0)                             1,288 (54.9)
   IV (very severe)                                                                          522 (22.4)                               414 (23.2)                             555 (23.7)
  Number of COPD maintenance medications,[d](#tfn5-copd-11-381){ref-type="table-fn"} n (%)                                                                                   
   0                                                                                         587 (25.2)                               475 (26.5)                             597 (25.4)
   1                                                                                         537 (23.0)                               440 (24.6)                             548 (23.3)
   2                                                                                         695 (29.8)                               569 (31.8)                             760 (32.3)
   3                                                                                         512 (22.0)                               307 (17.1)                             447 (19.0)

**Notes:** Data are given as mean (SD), unless otherwise stated.

Assessments of FEV~1~ and SGRQ were completed at baseline and month 2 (0--2-month responder analysis), and at baseline and months 2 and 12 (12-month responder and exacerbation rate analyses).

Measured at randomization.

GOLD COPD grades are defined as follows: grade II, postbronchodilator FEV~1~ 50%--80% of predicted; grade III, postbronchodilator FEV~1~ 30%--50% of predicted; and grade IV, postbronchodilator FEV~1~ \<30% of predicted.

The number of COPD maintenance medications is defined as follows: 0, no maintenance treatment with LA or ICS (short-acting bronchodilators only); 1, one LA or ICS; 2, two LA or ICS; 3, three LA or ICS. All patients received short-acting β~2~-agonists at inclusion so that a reversibility test could be conducted (GOLD classification based upon postbronchodilator FEV~1~). The majority of patients with a prebronchodilator FEV~1~ of 40%--50% had a postbronchodilator FEV~1~ of ≥50%, thus classifying them as having moderate COPD. Patients were recruited if they displayed a prebronchodilator FEV~1~ of ≤50%, but only postbronchodilator FEV~1~ values are presented here.

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LA, long-acting bronchodilator; SD, standard deviation; SGRQ, St George's Respiratory Questionnaire.

###### 

Demographic and clinical characteristics for all patients who received budesonide/formoterol, formoterol, or placebo, and by treatment group, in the two placebo-controlled trials included in the 0--2-month analysis

  Characteristics                                                                         Total (n=2,331)     Budesonide/formoterol (n=771)   Formoterol (n=779)   Placebo (n=781)
  --------------------------------------------------------------------------------------- ------------------- ------------------------------- -------------------- ------------------
  Age, years                                                                              63.1 (9.2)          63.2 (9.0)                      63.1 (9.3)           63.0 (9.3)
  Male, n (%)                                                                             1,526 (65.5)        496 (64.3)                      509 (65.3)           521 (66.7)
  BMI, kg/m^2^                                                                            26.8 (5.7)          26.6 (5.6)                      26.8 (5.6)           27.0 (5.9)
  Time since first symptoms, months                                                       127.2 (84.8)        126.0 (84.0)                    128.4 (85.1)         127.1 (85.3)
  FEV~1~                                                                                                                                                           
   Prebronchodilator, % predicted                                                         34.2 (9.7)          33.3 (9.6)                      34.1 (9.9)           35.1 (9.4)
   Prebronchodilator, L[a](#tfn8-copd-11-381){ref-type="table-fn"}                        1.0 (0.4)           1.0 (0.4)                       1.0 (0.4)            1.1 (0.4)
   Reversibility, % predicted                                                             5.5 (5.9)           5.4 (5.3)                       5.3 (5.8)            5.8 (6.5)
   Postbronchodilator, % predicted                                                        39.7 (11.9)         38.8 (11.5)                     39.4 (12.2)          41.0 (11.8)
  Prebronchodilator FEV~1~/FVC, %                                                         47.6 (10.4)         47.1 (10.4)                     47.5 (10.5)          48.3 (10.3)
  Smoking history                                                                                                                                                  
   Median, pack-years                                                                     40.0                40.0                            40.0                 40.0
   Former smokers, n (%)                                                                  1,343 (57.6)        455 (59.0)                      437 (56.1)           451 (57.7)
   Current smokers, n (%)                                                                 988 (42.4)          316 (41.0)                      342 (43.9)           330 (42.3)
  SGRQ total score,[a](#tfn8-copd-11-381){ref-type="table-fn"} points (range)             54.9 (6.7--100.0)   55.2 (6.7--100.0)               54.7 (16.4--97.4)    54.7 (8.8--96.9)
  Reliever use, no of inhalations (range)                                                 3.7 (0.0--32.5)     3.7 (0.0--21.6)                 3.9 (0.0--32.5)      3.5 (0.0--28.0)
  COPD severity (GOLD grades),[b](#tfn9-copd-11-381){ref-type="table-fn"} n (%)                                                                                    
   II (moderate)                                                                          436 (18.7)          136 (17.6)                      148 (19.0)           152 (19.5)
   III (severe)                                                                           1,364 (58.9)        443 (57.5)                      439 (56.4)           482 (61.7)
   IV (very severe)                                                                       522 (22.4)          191 (24.8)                      189 (24.3)           142 (18.2)
  No of COPD maintenance medications,[c](#tfn10-copd-11-381){ref-type="table-fn"} n (%)                                                                            
   0                                                                                      587 (25.2)          186 (24.1)                      195 (25.0)           206 (26.4)
   1                                                                                      537 (23.0)          176 (22.8)                      187 (24.0)           174 (22.3)
   2                                                                                      695 (29.8)          246 (31.9)                      222 (28.5)           227 (29.1)
   3                                                                                      512 (22.0)          163 (21.1)                      175 (22.5)           174 (22.3)

**Notes:** Data are given as mean (SD), unless otherwise stated.

Measured at randomization.

GOLD COPD grades are defined as follows: grade II, postbronchodilator FEV~1~ 50%--80% of predicted; grade III, postbronchodilator FEV~1~ \<30%--50% of predicted; and grade IV, postbronchodilator FEV~1~ \<30% of predicted.

The number of COPD maintenance medications is defined as follows: 0, no maintenance treatment with LA or ICS (short-acting bronchodilators only); 1, one LA or ICS; 2, two LA or ICS; and 3, three LA or ICS.

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LA, long-acting bronchodilator; SD, standard deviation; SGRQ, St George's Respiratory Questionnaire.

###### 

Analysis of 2-month response rates in FEV~1~ and SGRQ total score in patients who received budesonide/formoterol, formoterol alone, or placebo in the two placebo-controlled trials

                                                                 FEV~1~ response[a](#tfn12-copd-11-381){ref-type="table-fn"}   SGRQ response[b](#tfn13-copd-11-381){ref-type="table-fn"}                       
  -------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------- ------------------- -------
  **Odds of achieving response vs nonresponse**                                                                                                                                                                
  Budesonide/formoterol                                          0.79 (0.68--0.92)                                                                                                         0.98 (0.84--1.15)   
  Formoterol                                                     0.51 (0.43--0.60)                                                                                                         0.72 (0.62--0.85)   
  Placebo                                                        0.36 (0.30--0.43)                                                                                                         0.69 (0.59--0.82)   
  **Odds of achieving response with one treatment vs another**                                                                                                                                                 
  Budesonide/formoterol vs formoterol                            1.56 (1.25--1.95)                                             \<0.001                                                     1.36 (1.09--1.70)   0.006
  Budesonide/formoterol vs placebo                               2.21 (1.75--2.79)                                             \<0.001                                                     1.42 (1.13--1.78)   0.002
  Formoterol vs placebo                                          1.42 (1.12--1.81)                                             0.004                                                       1.04 (0.83--1.31)   0.72

**Notes:**

FEV~1~ response was defined as an improvement in the FEV~1~ of ≥100 mL.

SGRQ response was defined as an improvement (ie, reduction) in SGRQ total score of ≥4 points.

**Abbreviations:** CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; OR, odds ratio; SGRQ, St George's Respiratory Questionnaire.

###### 

Poisson regression analysis of exacerbation rates, by treatment, during months 2--12 in patients who received budesonide/formoterol or formoterol and who did and did not achieve FEV~1~ and SGRQ response at 2 months

                                                                             FEV~1~[a](#tfn15-copd-11-381){ref-type="table-fn"}   SGRQ[b](#tfn16-copd-11-381){ref-type="table-fn"}                       
  -------------------------------------------------------------------------- ---------------------------------------------------- -------------------------------------------------- ------------------- -------
  Treatment (rate)                                                                                                                                                                                       
   Budesonide/formoterol responders                                          0.60 (0.50--0.71)                                    NA                                                 0.69 (0.59--0.80)   NA
   Budesonide/formoterol nonresponders                                       0.82 (0.72--0.95)                                    NA                                                 0.77 (0.66--0.90)   NA
   Formoterol responders                                                     0.71 (0.59--0.86)                                    NA                                                 0.85 (0.73--0.99)   NA
   Formoterol nonresponders                                                  1.02 (0.90--1.15)                                    NA                                                 0.97 (0.84--1.11)   NA
   Budesonide/formoterol vs formoterol                                       0.82 (0.71--0.96)                                    0.012                                              0.80 (0.69--0.92)   0.002
  Response (ratio)                                                                                                                                                                                       
   Responders vs nonresponders                                               0.71 (0.61--0.83)                                    \<0.001                                            0.89 (0.77--1.03)   0.11
   Budesonide/formoterol responders vs budesonide/formoterol nonresponders   0.72 (0.58--0.90)                                    0.004                                              0.90 (0.73--1.11)   0.31
   Formoterol responders vs formoterol nonresponders                         0.70 (0.56--0.87)                                    0.001                                              0.88 (0.73--1.07)   0.21
   Budesonide/formoterol responders vs formoterol responders                 0.84 (0.65--1.08)                                    0.17                                               0.81 (0.66--0.99)   0.04
   Budesonide/formoterol nonresponders vs formoterol nonresponders           0.81 (0.68--0.96)                                    0.015                                              0.79 (0.65--0.97)   0.022
  Interaction                                                                1.04 (0.77--1.41)                                    0.81                                               1.02 (0.76--1.35)   0.92

**Notes:**

FEV~1~ response was defined as an improvement in FEV~1~ of ≥100 mL.

SGRQ response was defined as a reduction (ie, an improvement) in SGRQ total score of ≥4 points.

**Abbreviations:** CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; NA, not applicable; SGRQ, St George's Respiratory Questionnaire.

###### 

Poisson regression analysis of exacerbation rate from 2 to 12 months according to treatment type, baseline FEV~1~, and SGRQ total score, and FEV~1~ and SGRQ response at 2 months in patients who received budesonide/formoterol or formoterol

                                                                                     Contrast/regression coefficient (95% CI)   *P*-value
  ---------------------------------------------------------------------------------- ------------------------------------------ -----------
  FEV~1~[a](#tfn18-copd-11-381){ref-type="table-fn"}                                                                            
   2-month response (per 100 mL)                                                     0.92 (0.89--0.96)                          \<0.001
   Baseline FEV~1~ (per 100 mL increase)                                             0.91 (0.90--0.93)                          \<0.001
   Budesonide/formoterol vs formoterol[b](#tfn19-copd-11-381){ref-type="table-fn"}   0.83 (0.73--0.96)                          0.010
  SGRQ[c](#tfn20-copd-11-381){ref-type="table-fn"}                                                                              
   2-month response (per 4-point reduction)                                          0.95 (0.92--0.97)                          \<0.001
   Baseline SGRQ total score (per 4-point reduction)                                 0.97 (0.95--0.98)                          \<0.001
   Budesonide/formoterol vs formoterol[b](#tfn19-copd-11-381){ref-type="table-fn"}   0.82 (0.71--0.94)                          0.006

**Notes:**

FEV~1~ response was defined as an improvement in FEV~1~ of ≥100 mL.

Randomized comparison.

SGRQ response was defined as a reduction (ie, an improvement) in SGRQ total score of ≥4 points.

**Abbreviations:** CI, confidence interval; FEV~1~, forced expiratory volume in 1 second; NA, not applicable; SGRQ, St George's Respiratory Questionnaire.
